AbCellera Biologics (ABCL) said Tuesday it commenced an underwritten public offering of $200 million of common shares and, in place of common shares for certain investors, pre-funded warrants.

The company intends to use the net proceeds to fund research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and general corporate purposes.